The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
After years of awaiting results from clinical trials that included BTKi in frontline treatment combinations, the ECHO trial led to the FDA’s approval of the first BTKi in combination with chemoimmunotherapy.
Alan List, MD, speaks at 1:11 pm on Wednesday, September 9.
CELMoDs represent the next generation of cereblon-binding agents specifically designed to address this challenge. Iberdomide and mezigdomide have demonstrated encouraging activity in heavily pretreated and IMiD-refractory MM that led to their evaluation in the maintenance and frontline settings.
At 7 am CST on September 9, Ghayas C. Issa, MD, of the University of Texas MD Anderson Cancer Center in Houston, talks about the role of menin inhibitors in acute myeloid leukemia in today’s Meet-the-Professor session.
Dr. O’Brien, a founding member of the society, has contributed far beyond her scientific expertise. Known for her dedication and commitment to the field, she has supported SOHO’s growth and mission since the society’s earliest days.
These past two years have been plagued with instability, whether perceived or real, as well as a lack of transparency. The current environment cannot be ignored by the field in which we practice.
SOHO Insider is the official media platform of the Society of Hematologic Oncology. The SOHO Insider Editorial Board is comprised of leading hematologists. Learn more about our editorial board and SOHO Insider platforms.
To access the SOHO Career Center click the following link.
